In vivo Binding Behavior of Dopamine Receptor Agonist (+)-PD 128907 and Implications for the "Ceiling Effect" in Endogenous Competition Studies with [11C]raclopride - A Positron Emission Tomography Study in Macaca mulatta

Journal of Cerebral Blood Flow and Metabolism

Volumn 24, Issue 5, 2004, Pages 531-535

  Kortekaas, Rudie ^a,b   Maguire, R Paul ^a   Cremers, Thomas I ^a   Dijkstra, Durk ^a   Van Waarde, Aren ^b   Leenders, Klaus L ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Brain; D2 like receptors; Dopamine; Monkey; PET; 11C raclopride

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; CARBON 11; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; DOSE RESPONSE; MACACA; MALE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

EID: 2342543198     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-200405000-00007     Document Type: Article

References (15)

1. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-6
2. Dijkstra D, Mulder TB, Rollema H, Tepper PG, Van der Weide J, Horn AS (1988) Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]-1, 4-oxazin-7-and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation. J Med Chem 31:2178-2182
3. Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Hogberg T, Nilsson L, Sjogren I, Stone-Elander S (1988) Stereoselective binding of 11C-raclopride in living human brain-a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology 94:471-478
4. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18:941-50
5. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-51
6. Laruelle M, Iyer RN, al Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
7. Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88-118
8. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, et al. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-66
9. Schwarz J, Oertel WH, Tatsch K (1996) Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. J Nucl Med 37:1112-1115
10. Sun W, Ginovart N, Ko F, Seeman P, Kapur S (2003) In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. Mol Pharmacol 63:456-462
11. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002) Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse 45:207-212
12. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N (1999) Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys. Brain Res 841:160-9
13. Vermeulen RJ, Drukarch, Verhoeff NP, Goosen C, Sahadat MC, Wolters EC, van Royen EA, Stoof JC (1994) No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of[1231]IBZM as measured with SPECT in MPTP monkeys. Synapse 17:115-124
14. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, et al. (1994) Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16:255-62
15. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43